Paclitaxel plus carboplatin for advanced lung cancer: Preliminary results of a Vanderbilt University Phase II Trial - LUN-46

D. H. Johnson, D. M. Paul, K. R. Hande, R. F. DeVore

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Based on their good activity and minimal toxicity in non-small cell lung cancer and other cancers, we initiated a phase II trial of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in the treatment of patients with previously untreated stage IIIB and IV non-small cell lung cancer. Among 51 patients treated, the overall response rate was 27.5% (14 partial responses). Seventeen patients had stable disease, while 16 patients experienced disease progression after two cycles of treatment. Apart from myelosuppression, toxicity has been modest, with fewer than 5% of patients experiencing grade 3 or greater nonhematologic toxicity. Objective response and survival rates were modestly improved among patients given the higher of two paclitaxel doses (175 mg/m2 v 135 mg/m2). These data suggest that paclitaxel plus carboplatin warrants further study in metastatic non- small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)30-33
Number of pages4
JournalSeminars in oncology
Volume22
Issue number4 SUPPL. 9
StatePublished - Sep 4 1995

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Paclitaxel plus carboplatin for advanced lung cancer: Preliminary results of a Vanderbilt University Phase II Trial - LUN-46'. Together they form a unique fingerprint.

  • Cite this